Cleared Traditional

K772177 - TRI-TAB-RIA

K772177 is an FDA 510(k) clearance for TRI-TAB-RIA, manufactured by Nuclear Medical Laboratories, Inc.. The device is a Class 2 Immunology device with product code CDP cleared through the Traditional 510(k) pathway after a 31-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1977
Decision
31d
Days
Class 2
Risk

K772177 is an FDA 510(k) clearance for the TRI-TAB-RIA. Classified as Radioimmunoassay, Total Triiodothyronine (product code CDP), Class II - Special Controls.

Submitted by Nuclear Medical Laboratories, Inc. (Mchenry, US). The FDA issued a Cleared decision on December 22, 1977 after a review of 31 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 862.1710 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

FDA 510(k) Submission Details - K772177

510(k) Number K772177 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 21, 1977
Decision Date December 22, 1977
Days to Decision 31 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
74d faster than avg
Panel avg: 105d · This submission: 31d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

CDP Device Classification - Class 2, Special Controls

Product Code CDP Radioimmunoassay, Total Triiodothyronine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1710
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - CDP Radioimmunoassay, Total Triiodothyronine

All 143
Devices cleared under the same product code (CDP) and FDA review panel - the closest regulatory comparables to K772177.
GAMMA STIK 125I T3 UPTAKE KIT
K780492 · Alpha Gamma Laboratory · Apr 1978
TRIA-PEG RIA DIAG. KIT
K780292 · Nuclear Diagnostics, Inc. · Mar 1978
THYRO-INDICATOR T-3 125I
K780018 · Clinical Immuno-Diagnostics · Feb 1978
IN VITRO T3 RIA TEST
K772108 · Clinical Assays, Inc. · Nov 1977
T3 RIA KIT
K772122 · Antibodies, Inc. · Nov 1977
T3 RIA
K771623 · Hoffmann-La Roche, Inc. · Sep 1977